GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (NAS:AXNX) » Definitions » Beneish M-Score

Axonics (Axonics) Beneish M-Score : -2.05 (As of May. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Axonics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.05 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Axonics's Beneish M-Score or its related term are showing as below:

AXNX' s Beneish M-Score Range Over the Past 10 Years
Min: -2.83   Med: 3.8   Max: 20.26
Current: -2.05

During the past 8 years, the highest Beneish M-Score of Axonics was 20.26. The lowest was -2.83. And the median was 3.80.


Axonics Beneish M-Score Historical Data

The historical data trend for Axonics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics Beneish M-Score Chart

Axonics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial 14.19 3.69 4.52 -2.69 -2.03

Axonics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.66 -2.15 -1.98 -2.03 -2.05

Competitive Comparison of Axonics's Beneish M-Score

For the Medical Devices subindustry, Axonics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axonics's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Axonics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Axonics's Beneish M-Score falls into.



Axonics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Axonics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9608+0.528 * 0.9742+0.404 * 1.0656+0.892 * 1.3082+0.115 * 1.4443
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9253+4.679 * 0.025052-0.327 * 0.9962
=-2.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $50.5 Mil.
Revenue was 91.409 + 109.735 + 93.1 + 92.894 = $387.1 Mil.
Gross Profit was 69.253 + 82.76 + 69.104 + 70.19 = $291.3 Mil.
Total Current Assets was $482.0 Mil.
Total Assets was $715.6 Mil.
Property, Plant and Equipment(Net PPE) was $17.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $12.9 Mil.
Selling, General, & Admin. Expense(SGA) was $251.8 Mil.
Total Current Liabilities was $48.4 Mil.
Long-Term Debt & Capital Lease Obligation was $30.2 Mil.
Net Income was -19.112 + 6.574 + 3.928 + -7.342 = $-16.0 Mil.
Non Operating Income was -3.827 + -3.531 + 0 + -16.049 = $-23.4 Mil.
Cash Flow from Operations was -9.236 + 5.63 + 12.344 + -19.209 = $-10.5 Mil.
Total Receivables was $40.2 Mil.
Revenue was 70.65 + 85.918 + 70.384 + 68.98 = $295.9 Mil.
Gross Profit was 52.5 + 62.967 + 51.26 + 50.196 = $216.9 Mil.
Total Current Assets was $469.7 Mil.
Total Assets was $665.7 Mil.
Property, Plant and Equipment(Net PPE) was $7.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $11.5 Mil.
Selling, General, & Admin. Expense(SGA) was $208.0 Mil.
Total Current Liabilities was $66.2 Mil.
Long-Term Debt & Capital Lease Obligation was $7.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(50.529 / 387.138) / (40.2 / 295.932)
=0.130519 / 0.135842
=0.9608

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(216.923 / 295.932) / (291.307 / 387.138)
=0.733016 / 0.752463
=0.9742

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (482.03 + 17.037) / 715.561) / (1 - (469.671 + 7.017) / 665.691)
=0.302551 / 0.28392
=1.0656

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=387.138 / 295.932
=1.3082

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(11.505 / (11.505 + 7.017)) / (12.856 / (12.856 + 17.037))
=0.621153 / 0.430067
=1.4443

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(251.789 / 387.138) / (208.003 / 295.932)
=0.650386 / 0.702874
=0.9253

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((30.154 + 48.387) / 715.561) / ((7.178 + 66.17) / 665.691)
=0.109761 / 0.110183
=0.9962

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-15.952 - -23.407 - -10.471) / 715.561
=0.025052

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Axonics has a M-score of -2.05 suggests that the company is unlikely to be a manipulator.


Axonics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Axonics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Axonics (Axonics) Business Description

Traded in Other Exchanges
Address
26 Technology Drive, Irvine, CA, USA, 92618
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.
Executives
Karen Noblett officer: Chief Medical Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Kari Leigh Keese officer: Chief Financial Officer 15205 LAFAYETTE WAY, TUSTIN CA 92782
Danny L. Dearen officer: See Remarks 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Ford Alfred J Jr officer: Chief Commercial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Rinda Sama officer: Chief Operating Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
John Woock officer: Chief Marketing Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Raymond W Cohen director, officer: Chief Executive Officer
Esteban Lopez director 6303 COWBOYS WAY, SUITE 600, FRISCO TX 75034
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
David M Demski director C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert E Mcnamara director C/O NORTHSTAR NEUROSCIENCE, INC., 2401 FOURTH AVENUE, SUITE 300, SEATTLE WA 98121
Bakker Juliet Tammenoms director, 10 percent owner LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Partners Andera 10 percent owner 374 RUE SAINT ST HONORE, PARIS I0 75001
Raphael Wisniewski director, 10 percent owner 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920